A Systematic Review of the Prevalence of Schizophrenia, PLOS Med, vol.2, issue.5, p.141, 2005. ,
An evaluation of variation in published estimates of schizophrenia prevalence from 1990?2013: a systematic literature review, BMC Psychiatry, vol.15, p.193, 2015. ,
The Global burden of disease : a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 : summary, 1996. ,
A Concise Overview of Incidence, Prevalence, and Mortality, Epidemiol Rev, vol.30, issue.1, pp.67-76, 2008. ,
Negative symptoms and depression predict lower psychological well-being in individuals with schizophrenia, Compr Psychiatry, vol.53, issue.8, pp.1137-1181, 2012. ,
Les rechutes psychotiques dans la schizophrénie, Neurone, vol.7, p.6, 2002. ,
, Am J Psychiatry, vol.145, issue.11, pp.1446-1455, 1988.
Symptômes négatifs de la schizophrénie : une revue des instruments d'évaluation. L'Encéphale, vol.42, pp.165-71, 2016. ,
Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms, Schizophr Bull, vol.42, issue.3, pp.571-579, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01575633
, Epilepsy : its symptoms, treatment, and relation to other chronic convulsive diseases, pp.1828-1896
, , p.1861
The principles of psychology, p.1895 ,
Remarks on dissolution of the nervous system as exemplified by certain post-epileptic conditions, vol.35, pp.399-402, 1881. ,
Positive and negative cerebral symptoms: the roles of Russell Reynolds and Hughlings Jackson, J Neurol Neurosurg Psychiatry, vol.75, issue.8, p.1148, 2004. ,
Traité des maladies mentales, p.1860 ,
,
, , vol.41, pp.6-9, 2015.
,
Leçons cliniques sur la démence précoce et la psychose maniacodépressive, 1899. ,
Eugen Bleuler's Dementia Praecox or the Group of Schizophrenias (1911): A Centenary Appreciation and Reconsideration, Schizophr Bull, vol.37, issue.3, pp.471-480, 2011. ,
Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research, Clin Psychol Rev, vol.31, issue.1, pp.161-169, 2011. ,
Hughlings jackson's principles and the organo-dynamic concept of psychiatry, Am J Psychiatry, vol.118, issue.8, pp.673-82, 1962. ,
Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. International record of medicine and general practice clinics, vol.168, p.318, 1955. ,
Molecular pathology of schizophrenia: more than one disease process?, Br Med J, vol.280, issue.6207, pp.66-74, 1980. ,
Negative Symptoms in Schizophrenia: Definition and Reliability. Arch Gen Psychiatry, vol.39, pp.784-792, 1982. ,
The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations, Br J Psychiatry Suppl, issue.7, pp.49-58, 1989. ,
Correlational studies of the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms: an overview and update, Psychopathology, vol.28, issue.1, pp.7-17, 1995. ,
The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, vol.13, issue.2, pp.261-76, 1987. ,
Deficit and nondeficit forms of schizophrenia: the concept, Am J Psychiatry, vol.145, issue.5, pp.578-83, 1988. ,
The schedule for the deficit syndrome: An instrument for research in schizophrenia, Psychiatry Res, vol.30, issue.2, pp.119-142, 1989. ,
Schedule for evaluation of the deficit syndrome in schizophrenia: Schedule for Deficit Syndrome (SDS) (Kirkpatrick et al.). Importance pertinence of the SDS ,
, , vol.20, pp.413-422, 1994.
Le traitement des formes déficitaires de schizophrénie. L'Encéphale, vol.33, pp.11-16, 2007. ,
Negative symptoms, past and present: a historical perspective and moving to DSM-5, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.24, issue.5, pp.710-734, 2014. ,
The NIMH-MATRICS consensus statement on negative symptoms, Schizophr Bull, vol.32, issue.2, pp.214-223, 2006. ,
Negative symptoms and cognitive deficits: what is the nature of their relationship?, Schizophr Bull, vol.32, issue.2, pp.250-258, 2006. ,
What are the functional consequences of neurocognitive deficits in schizophrenia?, Am J Psychiatry, vol.153, issue.3, pp.321-351, 1996. ,
A separate disease within the syndrome of schizophrenia, Arch Gen Psychiatry, vol.58, issue.2, pp.165-71, 2001. ,
Stability of the diagnosis of deficit syndrome in schizophrenia, Am J Psychiatry, vol.156, pp.637-646, 1999. ,
Periods of recovery in deficit syndrome schizophrenia: a 20-year multi-follow-up longitudinal study, Schizophr Bull, vol.36, issue.4, pp.788-99, 2010. ,
Gray Matter Volume Alterations in Firstepisode Drug-naïve Patients with Deficit and Nondeficit Schizophrenia, Psychiatry Res, vol.234, issue.2, pp.219-245, 2015. ,
Odor Identification, Eye Tracking and Deficit Syndrome Schizophrenia, Biol Psychiatry, vol.51, issue.10, pp.809-824, 2002. ,
Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study, Neuropsychiatr Dis Treat, vol.12, pp.1261-1269, 2016. ,
Facial emotion recognition and alexithymia in Chinese male patients with deficit schizophrenia, Psychiatry Res, vol.246, pp.353-362, 201630. ,
Characterization of premorbid functioning during childhood in patients with deficit vs. non-deficit schizophrenia and in their healthy siblings, Schizophr Res, vol.174, issue.1-3, pp.172-178, 2016. ,
Categorizing and assessing negative symptoms, Curr Opin Psychiatry, vol.30, issue.3, pp.201-209, 2017. ,
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.23, issue.3, pp.196-204, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01665221
Neuroimaging predictors of functional outcomes in schizophrenia at baseline and 6-month follow-up, Schizophr Res, vol.169, issue.1-3, pp.69-75, 2015. ,
Premorbid, clinical and cognitive correlates of primary negative symptoms in first-episode psychosis, Psychiatry Res, vol.242, pp.144-153, 201630. ,
The stability of negative syndrome, persistent negative syndrome and deficit syndrome in a twenty-year follow-up study of schizophrenia patients, Psychiatry Res, vol.238, pp.236-277, 2016. ,
Deficit psychopathology and a paradigm shift in schizophrenia research, Biol Psychiatry, vol.46, issue.3, pp.352-60, 1999. ,
Negative symptoms of schizophrenia: Clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment, Eur Neuropsychopharmacol, vol.24, issue.5, pp.645-92, 2014. ,
Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities, Schizophr Bull, vol.34, issue.6, pp.1211-1231, 2008. ,
Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5, Schizophr Res, vol.150, issue.1, pp.15-20, 2013. ,
Structure of the psychotic disorders classification in DSM-5, Schizophr Res, vol.150, issue.1, pp.11-15, 2013. ,
The Negative Symptoms of Schizophrenia: Category or Continuum?, Psychopathology, vol.44, issue.6, pp.345-53, 2011. ,
Longitudinal assessment of negative symptoms in schizophrenia/schizoaffective patients, other psychotic patients, and depressed patients, Schizophr Bull, vol.27, issue.3, pp.527-564, 2001. ,
The Structure of Negative Symptoms Within Schizophrenia: Implications for Assessment, vol.32, pp.238-283, 2006. ,
Negative symptoms in schizophrenia: a confirmatory factor analysis of competing models, Am J Psychiatry, vol.152, issue.10, pp.1450-1457, 1995. ,
Empirical validation of primary negative symptoms: independence from effects of medication and psychosis, Am J Psychiatry, vol.156, issue.3, pp.406-417, 1999. ,
Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.24, issue.5, pp.693-709, 2014. ,
Texte imprimé] : critères diagnostiques / American psychiatric association ; coordination générale de la traduction française ,
Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome, J Psychiatr Res, vol.47, issue.6, pp.783-90, 2013. ,
The brief negative symptom scale: psychometric properties, Schizophr Bull, vol.37, issue.2, pp.300-305, 2011. ,
The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation, Am J Psychiatry, vol.170, issue.2, pp.165-72, 2013. ,
Negative Symptoms in Schizophrenia: Avolition and Occam's Razor, Schizophr Bull, vol.36, issue.2, pp.359-69, 2010. ,
, Lancet Lond Engl, vol.374, issue.9690, pp.635-680, 2009.
Negative symptoms of schizophrenia: new developments and unanswered research questions, Lancet Psychiatry, vol.5, issue.8, pp.664-77, 2018. ,
Negative Features, Retrieval Processes and Verbal Fluency in Schizophrenia, Br J Psychiatry, vol.163, issue.6, pp.769-75, 1993. ,
Disorganization of semantic memory underlies alogia in schizophrenia: An analysis of verbal fluency performance in Japanese subjects, Schizophr Res, vol.74, issue.1, pp.91-100, 2005. ,
Speech deficits in serious mental illness: a cognitive resource issue? Schizophr Res, vol.160, pp.173-182, 2014. ,
L'apathie dans la schizophrénie: une revue clinique et critique de la question, Encéphale, vol.pii, issue.13, pp.150-154, 2013. ,
Definition and description of schizophrenia in the DSM-5, Schizophr Res, vol.150, issue.1, pp.3-10, 2013. ,
, Random House Webster's Unabridged Dictionary, 2006.
The History of Mental Symptoms by ,
, , 1996.
Apathy: A neuropsychiatric syndrome, J Neuropsychiatry Clin Neurosci, vol.3, issue.3, pp.243-54, 1991. ,
The nosological position of apathy in clinical practice, J Neurol Neurosurg Psychiatry, vol.79, issue.10, pp.1088-92, 2008. ,
Apathy: why care?, J Neuropsychiatry Clin Neurosci, vol.17, issue.1, pp.7-19, 2005. ,
Disorders of diminished motivation, J Head Trauma Rehabil, vol.20, issue.4, pp.377-88, 2005. ,
Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits, Cereb Cortex N Y N, vol.16, issue.7, pp.916-944, 1991. ,
, Alzheimer et maladies apparentées : diagnostic et prise en charge de l'apathie RECOMMANDATION DE BONNE PRATIQUE -Mis en ligne le 09 oct, 2014.
Apathy in schizophrenia: clinical correlates and association with functional outcome, Schizophr Res, vol.63, issue.1-2, pp.79-88, 2003. ,
Distress attributed to negative symptoms in schizophrenia, Schizophr Bull, vol.26, issue.3, pp.737-781, 2000. ,
Behavioral approach and avoidance in schizophrenia: an evaluation of motivational profiles, Schizophr Res, vol.159, issue.1, pp.164-70, 2014. ,
Effort, Anhedonia, and Function in Schizophrenia: Reduced Effort Allocation Predicts Amotivation and Functional Impairment, J Abnorm Psychol, vol.123, issue.2, pp.387-97, 2014. ,
Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making, J Psychiatr Res, vol.47, issue.11, pp.1590-1596, 2013. ,
Negative Symptoms of Schizophrenia Are Associated with Abnormal Effort-Cost Computations, Biol Psychiatry, vol.74, issue.2, pp.130-136, 2013. ,
Separate valuation subsystems for delay and effort decision costs, J Neurosci Off J Soc Neurosci, vol.30, issue.42, pp.14080-90, 2010. ,
Hedonic capacity: some conjectures, Bull Menninger Clin, vol.39, issue.4, pp.295-307, 1975. ,
Anhedonia in Schizophrenia: A Review of Assessment Strategies, Schizophr Bull, vol.32, issue.2, pp.259-73, 2006. ,
Diagnostic differences in social anhedonia: a longitudinal study of schizophrenia and major depressive disorder, J Abnorm Psychol, vol.110, issue.3, pp.363-71, 2001. ,
Looking at the other side of the coin: a meta-analysis of selfreported emotional arousal in people with schizophrenia, Schizophr Res, vol.142, issue.1-3, pp.65-70, 2012. ,
Episodic and semantic knowledge in emotional self-report: evidence for two judgment processes, J Pers Soc Psychol, vol.83, issue.1, pp.198-215, 2002. ,
Association of physical and social anhedonia with depression in the acute phase of schizophrenia, Psychopathology, vol.41, issue.6, pp.365-70, 2008. ,
Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure, Schizophr Res, vol.93, issue.1-3, pp.253-60, 2007. ,
Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback, Psychol Med, vol.45, issue.8, pp.1765-78, 2015. ,
Mechanisms Underlying Motivational Deficits in Psychopathology: Similarities and Differences in Depression and Schizophrenia, Curr Top Behav Neurosci, vol.27, pp.411-460, 2016. ,
A review of reward processing and motivational impairment in schizophrenia, Schizophr Bull, vol.40, issue.2, pp.107-116, 2014. ,
Low-pleasure beliefs in patients with schizophrenia and individuals with social anhedonia, Schizophr Res, 2018. ,
Remembering the past to imagine the future: the prospective brain, Nat Rev Neurosci, vol.8, issue.9, pp.657-61, 2007. ,
Social cognition and psychopathology: a critical overview, World Psychiatry Off J World Psychiatr Assoc WPA, vol.14, issue.1, pp.5-14, 2015. ,
Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia, Schizophr Res, vol.146, issue.1-3, pp.231-238, 2013. ,
Movement, face processing and schizophrenia: evidence of a differential deficit in expression analysis, Br J Clin Psychol, vol.33, pp.517-545, 1994. ,
Schizophrenic patients' sensitivity to social cues: the role of abstraction, Am J Psychiatry, vol.150, issue.4, pp.589-94, 1993. ,
Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences, Am J Psychiatry, vol.154, issue.11, pp.1544-50, 1997. ,
Comparison of social cognitive functioning in schizophrenia and high functioning autism: more convergence than divergence, Psychol Med, vol.40, issue.4, pp.569-79, 2010. ,
The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation, Am J Psychiatry, vol.170, issue.2, pp.165-72, 2013. ,
Social cognition in schizophrenia: relationships with neurocognition and negative symptoms, Schizophr Res, vol.90, issue.1-3, pp.316-340, 2007. ,
Peripheral oxytocin is associated with reduced symptom severity in schizophrenia, Schizophr Res, vol.124, issue.1-3, pp.13-21, 2010. ,
Emotion dysregulation in schizophrenia: reduced amplification of emotional expression is associated with emotional blunting, Schizophr Res, vol.95, issue.1-3, pp.197-204, 2007. ,
Characterization of the facial expression of emotions in schizophrenia patients: preliminary findings with a new electromyography method, Can J Psychiatry Rev Can Psychiatr, vol.51, issue.6, pp.335-376, 2006. ,
Do we recognize facial expressions of emotions from persons with schizophrenia?, Schizophr Res, vol.122, issue.1-3, pp.144-50, 2010. ,
A review of emotion deficits in schizophrenia, Dialogues Clin Neurosci, vol.8, issue.1, pp.59-70, 2006. ,
Speech deficits in serious mental illness: a cognitive resource issue? Schizophr Res, vol.160, pp.173-182, 2014. ,
Video-based quantification of body movement during social interaction indicates the severity of negative symptoms in patients with schizophrenia, Schizophr Res, vol.121, issue.1-3, pp.90-100, 2010. ,
Stability of emotional responding in schizophrenia, Behav Ther, vol.30, issue.3, pp.373-88, 1999. ,
Emotional Response Deficits in Schizophrenia: Insights From Affective Science, Schizophr Bull, vol.34, issue.5, pp.819-853, 2008. ,
Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures, Schizophr Bull, vol.32, issue.2, pp.279-87, 2006. ,
Nonverbal social communication and gesture control in schizophrenia, Schizophr Bull, vol.41, issue.2, pp.338-383, 2015. ,
Electrophysiological aberrations associated with negative symptoms in schizophrenia, Curr Top Behav Neurosci, vol.21, pp.129-56, 2014. ,
Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia, Schizophr Bull, vol.34, issue.2, pp.393-401, 2008. ,
Impairments of executive/attentional functions in schizophrenia with primary and secondary negative symptoms, Psychiatry Res, vol.133, issue.1, pp.45-55, 2005. ,
URL : https://hal.archives-ouvertes.fr/hal-00018692
Secondary negative symptoms -A review of mechanisms, assessment and treatment, Schizophr Res, vol.186, pp.29-38, 2017. ,
Impact of primary negative symptoms on functional outcomes in schizophrenia, Eur Psychiatry J Assoc Eur Psychiatr, vol.29, issue.7, pp.449-55, 2014. ,
Demoralization in Medical Practice, Prim Care Companion J Clin Psychiatry, vol.9, issue.2, pp.139-182, 2007. ,
, , p.2014
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs, Psychol Med, vol.10, issue.1, pp.55-72, 1980. ,
Neuroleptic dysphoria: towards a new synthesis, Psychopharmacology (Berl), vol.171, issue.2, pp.121-153, 2004. ,
Correspondence between negative symptoms and potential sources of secondary negative symptoms over time. Eur Arch Psychiatry Clin Neurosci, 2017. ,
Psychiatric Comorbidities and Schizophrenia, vol.35, pp.383-402, 2009. ,
A systematic review of instruments to measure depressive symptoms in patients with schizophrenia, J Affect Disord, vol.140, issue.1, pp.38-47, 2012. ,
Assessing depression in schizophrenia: the Calgary Depression Scale, Br J Psychiatry Suppl, pp.39-44, 1993. ,
Depressive symptoms in schizophrenic patients, Eur J Med Res, vol.16, issue.12, pp.549-52, 2011. ,
Depression bei Schizophrenie. Fortschritte Neurol · Psychiatr, vol.83, pp.238-286, 2015. ,
,
, , vol.42, pp.18-22, 2016.
Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study, JAMA, vol.264, issue.19, pp.2511-2519, 1990. ,
Smoking and schizophrenia: epidemiological and clinical features ,
, , vol.34, pp.299-305, 2008.
Substance misuse in patients with schizophrenia: epidemiology and management, Drugs, vol.62, issue.5, pp.743-55, 2002. ,
High-potency cannabis and the risk of psychosis, Br J Psychiatry J Ment Sci, vol.195, issue.6, pp.488-91, 2009. ,
The Effect of Changes in Cannabis Exposure on Psychotic Symptoms in Patients With Comorbid Cannabis Use Disorder, J Dual Diagn, vol.12, issue.2, pp.129-165, 2016. ,
Drug abuse in schizophrenic patients: clinical correlates and reasons for use, Am J Psychiatry, vol.148, issue.2, pp.224-254, 1991. ,
Why do patients with psychosis use cannabis and are they ready to change their use?, Int J Dev Neurosci, vol.29, issue.3, pp.335-381, 2011. ,
Revisiting the 'self-medication' hypothesis in light of the new data linking low striatal dopamine to comorbid addictive behavior, Ther Adv Psychopharmacol, vol.5, issue.3, pp.172-180, 2015. ,
Can antipsychotic treatment contribute to drug addiction in schizophrenia?, Prog Neuropsychopharmacol Biol Psychiatry, vol.52, pp.9-16, 2014. ,
The Acquisition, Maintenance and Treatment of Polydrug Dependence: A Public Health Model, J Psychedelic Drugs, vol.7, issue.2, pp.209-222, 1975. ,
The reliability of distinguishing primary versus secondary negative symptoms, Compr Psychiatry, vol.36, issue.6, pp.421-428, 1995. ,
Differentiating Primary From Secondary Negative Symptoms in Schizophrenia: A Study of Neuroleptic-Naive Patients Before and After Treatment, Am J Psychiatry, vol.157, issue.9, pp.1461-1467, 2000. ,
Predominance of symptoms over time in early-onset psychosis: a principal component factor analysis of the Positive and Negative Syndrome Scale, J Clin Psychiatry, vol.71, issue.3, pp.327-364, 2010. ,
Les symptômes non spécifiques de la transition psychotique. L'Encéphale, vol.37, pp.10-14, 2011. ,
Diagnostic profile of inpatients as a determinant of length of stay in a general hospital psychiatric unit, Braz J Med Biol Res, vol.36, pp.1233-1273, 2003. ,
Assessing predictive factors for extended hospitalization at acute psychiatric admission, Psychiatr Serv, vol.52, pp.1367-73, 2001. ,
Clinical characteristics and length of hospital stay among older adults with bipolar disorder, schizophrenia or schizoaffective disorder, depression, and dementia, J Geriatr Psychiatry Neurol, vol.17, pp.3-8, 2004. ,
Assessing the efficacy of treatments for the deficit syndrome of schizophrenia, Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol, vol.22, issue.3, pp.303-313, 2000. ,
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, Lancet Lond Engl, vol.373, issue.9657, pp.31-41, 2009. ,
Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia, J Clin Psychiatry, vol.60, pp.9-12, 1999. ,
Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, p.6633, 2010. ,
A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia, CNS Drugs, vol.30, issue.1, pp.27-39, 2016. ,
Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials, Schizophr Bull, vol.41, issue.4, pp.892-901, 2015. ,
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia, World J Biol Psychiatry, vol.6, issue.3, pp.132-91, 2005. ,
Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials, Int J Neuropsychopharmacol, vol.7, issue.1, pp.15-20, 2004. ,
Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev, p.5581, 2006. ,
Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis, Br J Psychiatry, vol.197, issue.3, pp.174-183, 2010. ,
Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis, J Clin Psychiatry, vol.68, issue.4, pp.604-614, 2007. ,
Do antidepressants improve negative symptoms in schizophrenia?, BMJ, vol.342, p.3371, 2011. ,
The effects of bupropion on negative symptoms in schizophrenia, Iran J Pharm Res IJPR, vol.13, issue.4, pp.1227-1260, 2014. ,
Amelioration of deficit syndrome of schizophrenia by norepinephrine reuptake inhibitor, Ther Adv Psychopharmacol, vol.5, issue.5, pp.263-70, 2015. ,
Mirtazapine adjunct for people with schizophrenia, Cochrane Database Syst Rev, vol.5, p.11943, 201826. ,
Provocative tests with psychostimulant drugs in schizophrenia, Psychopharmacology (Berl), vol.91, issue.4, pp.415-448, 1987. ,
Stimulant drug treatment in childhood-onset schizophrenia with comorbid ADHD: an open-label case series, J Child Adolesc Psychopharmacol, vol.14, issue.3, pp.448-54, 2004. ,
A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities, Schizophr Res, vol.147, issue.2-3, pp.241-52, 2013. ,
Intractability of Deficit Syndrome of Schizophrenia Against Adjunctive Modafinil, J Clin Psychopharmacol, vol.36, issue.1, pp.45-54, 2016. ,
Adjunctive Lisdexamfetamine Dimesylate Therapy in Adult Outpatients With Predominant Negative Symptoms of Schizophrenia: Open-Label and Randomized-Withdrawal Phases, Neuropsychopharmacology, vol.38, issue.11, pp.2140-2149, 2013. ,
The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis, Schizophr Res, vol.109, issue.1-3, pp.10-14, 2009. ,
Drug development in schizophrenia: are glutamatergic targets still worth aiming at? Curr Opin Psychiatry, vol.28, pp.207-222, 2015. ,
Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia, CNS Drugs, vol.25, issue.10, pp.859-85, 2011. ,
Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis, Curr Pharm Des, vol.16, issue.5, pp.522-559, 2010. ,
D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial, Lancet Psychiatry, vol.2, issue.5, pp.403-415, 2015. ,
Psychopharmacology of the negative symptoms: current status and prospects for progress, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.24, issue.5, pp.788-99, 2014. ,
Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?, Curr Pharm Des, vol.21, issue.26, pp.3771-87, 2015. ,
Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study, J Clin Psychopharmacol, vol.33, issue.3, pp.336-378, 2013. ,
Memantine as an Augmentation Treatment for Schizophrenia: Limitations of Meta-Analysis for Evidence-Based Evaluation of Research, J Clin Psychiatry, vol.78, issue.9, pp.1307-1316, 2017. ,
Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature, CNS Drugs, vol.24, issue.4, pp.303-320, 2010. ,
Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev, vol.1, p.7967, 2012. ,
Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy, Br J Psychiatry, vol.203, issue.3, pp.172-180, 2013. ,
The role of 5-HT2A receptors in antipsychotic activity, Life Sci, vol.56, issue.25, pp.2209-2231, 1995. ,
Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial, Br J Psychiatry J Ment Sci, vol.163, pp.451-456, 1993. ,
Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study, Prog Neuropsychopharmacol Biol Psychiatry, vol.32, issue.8, pp.1879-83, 2008. ,
Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review, Neuromolecular Med, vol.16, issue.1, pp.61-70, 2014. ,
Schizophrenia and the influence of male gender, Clin Pharmacol Ther, vol.98, issue.6, pp.578-81, 2015. ,
Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia, Schizophr Res, vol.58, issue.1, pp.69-74, 2002. ,
Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on twocenter trial, Psychiatry Clin Neurosci, vol.68, issue.6, pp.432-472, 2014. ,
Add-On Pregnenolone with L-Theanine to Antipsychotic Therapy Relieves Negative and Anxiety Symptoms of Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial, Clin Schizophr Relat Psychoses, vol.12, issue.1, pp.31-41, 2018. ,
Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial, Schizophr Bull, vol.42, issue.2, pp.309-326, 2016. ,
Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials, Eur Arch Psychiatry Clin Neurosci, vol.266, issue.5, pp.439-50, 2016. ,
The role of inflammation in schizophrenia, Front Neurosci, vol.9, p.372, 2015. ,
Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials, Hum Psychopharmacol, vol.29, issue.5, pp.483-91, 2014. ,
, Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements, vol.36, pp.71-93, 2009.
Can repetitive transcranial magnetic stimulation be considered effective treatment option for negative symptoms of schizophrenia?, J ECT, vol.29, issue.1, pp.67-74, 2013. ,
Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis, Psychiatry Res, vol.215, issue.3, pp.505-518, 2014. ,
Psychosocial treatments for negative symptoms in schizophrenia: Current practices and future directions, Clin Psychol Rev, vol.33, issue.8, pp.914-942, 2013. ,
, Schizophrenia PORT Psychosocial Treatment Recommendations and Summary Statements, vol.36, pp.48-70, 2009.
Adapted cognitivebehavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression, Psychol Med, vol.45, issue.3, pp.453-65, 2015. ,
Effects of occupational therapy on hospitalized chronic schizophrenia patients with severe negative symptoms, Kobe J Med Sci, vol.57, issue.4, pp.145-154, 2012. ,
Psychological interventions for psychosis: a meta-analysis of comparative outcome studies, Am J Psychiatry, vol.171, issue.5, pp.523-561, 2014. ,
Treatment of negative symptoms: Where do we stand, and where do we go?, Schizophr Res, vol.186, pp.55-62, 2017. ,
A randomized pilot study of MOtiVation and Enhancement training (MOVE) for negative symptoms in schizophrenia, Schizophr Res, vol.165, issue.0, pp.175-80, 2015. ,
Cognitive Enhancement Therapy for Schizophrenia: Effects of a 2-Year Randomized Trial on Cognition and Behavior. Arch Gen Psychiatry, vol.61, pp.866-76, 2004. ,
Improvisational music therapy and the rehabilitation of persons suffering from chronic schizophrenia, J Music Ther, vol.31, issue.2, pp.86-104, 1994. ,
Management of negative symptoms among patients with schizophrenia attending multiple-family groups, Psychiatr Serv Wash DC, vol.51, issue.4, pp.513-522, 2000. ,
Symptômes négatifs de la schizophrénie : approches psychothérapeutiques. L'Encéphale, vol.41, pp.6-57, 2015. ,
A pilot study of loving-kindness meditation for the negative symptoms of schizophrenia, Schizophr Res, vol.129, issue.2-3, pp.137-177, 2011. ,
Anticipatory pleasure skills training: a new intervention to reduce anhedonia in schizophrenia, Perspect Psychiatr Care, vol.46, issue.3, pp.171-81, 2010. ,
Length of hospitalisation for people with severe mental illness, Cochrane Database Syst Rev, vol.2, p.384, 2000. ,
Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia, Psychopathology, vol.40, issue.2, pp.83-92, 2007. ,
The Motivation and Pleasure Scale Self-Report (MAP-SR): Reliability and validity of a self-report measure of negative symptoms, Compr Psychiatry, vol.54, issue.5, pp.568-574, 2013. ,
Assessment and self-assessment of patients'' attidudes troward their psychotic disorders, Psychiatr Pol, vol.31, issue.3, pp.47-48, 1997. ,
Patient education about schizophrenia: initial expectations and later satisfaction, Issues Ment Health Nurs, vol.22, issue.3, pp.3325-333, 2001. ,
Specificity and sensitivity of the Self-assessment of Negative Symptoms (SNS) in patients with schizophrenia, Schizophr Res, vol.211, pp.51-56, 2019. ,
The Brief Psychiatric Rating Scale, Psychol Rep, vol.10, issue.3, pp.799-812, 1962. ,
, Communiqué de presse : La variabilité de la prise en charge de la schizophrénie dans les établissements de santé en 2011 -IRDES, 2018.
Drug management of agitation in emergency departments: theoretical recommendations and studies of practices ,
URL : https://hal.archives-ouvertes.fr/hal-02447574
, Presse Medicale Paris Fr, vol.44, issue.1, pp.20-26, 1983.
,
, , vol.37, pp.83-89, 2011.
Naturalistic pharmacotherapy of acute episodes of schizophrenic disorders in comparison to treatment guidelines, Pharmacopsychiatry, vol.45, issue.5, pp.189-95, 2012. ,
Current perspectives on chlorpromazine equivalents: Comparing apples and oranges!, Indian J Psychiatry, vol.55, issue.2, pp.207-215, 2013. ,
, Benzodiazepine Equivalence Table, 2018.
Chlorpromazine equivalent doses for the newer atypical antipsychotics, J Clin Psychiatry, vol.64, issue.6, pp.663-670, 2003. ,
Practice Guideline for the Treatment of Partients with Schizophrenia, Second Edition, SUPPL.). Available, vol.from, issue.2, p.132, 2004. ,
,
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets, Eur Neuropsychopharmacol, vol.15, issue.1, pp.111-118, 2005. ,
The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients, J Clin Pharmacol, vol.27, issue.2, pp.144-50, 1987. ,
Clinical utility of the Calgary Depression Scale for Schizophrenia in individuals at ultra-high risk of psychosis, Schizophr Res, 2017. ,
,
, , 2017.
Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients, Nord J Psychiatry, vol.67, issue.1, pp.22-31, 2013. ,
Positive and negative subtypes of schizophrenia. A follow-up study from India, Schizophr Res, vol.3, issue.2, pp.107-123, 1990. ,
Changes in the Positive and Negative Symptoms of Schizophrenic In-patients in China, Br J Psychiatry, vol.159, issue.2, pp.226-257, 1991. ,
Assessment of enduring deficit and negative symptom subtypes in schizophrenia, Schizophr Bull, vol.17, issue.4, pp.565-82, 1991. ,
Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data, Psychol Med, vol.45, issue.8, pp.1613-1640, 2015. ,
The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study, Schizophr Res, vol.189, pp.84-90, 2017. ,
Negative symptoms in schizophrenia: their evolution during an acute phase, Schizophr Res, vol.17, issue.2, pp.187-94, 1995. ,
A Psychometric Comparison of the Clinical Assessment Interview for Negative Symptoms and the Brief Negative Symptom Scale, Schizophr Bull, vol.42, issue.6, pp.1384-94, 2016. ,
Negative symptoms in schizophrenia: their longitudinal course and prognostic importance, Schizophr Bull, vol.11, issue.3, pp.427-466, 1985. ,
Positive and negative symptoms of schizophrenia: Their course and relationship over time, Schizophr Res, vol.5, issue.1, pp.51-60, 1991. ,
Use of antipsychotics in the treatment of depressive disorders. Shanghai Arch Psychiatry, vol.25, pp.134-174, 2013. ,
Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use, Aust N Z J Psychiatry, vol.48, issue.5, pp.418-450, 2014. ,
Durées d'hospitalisation des patients souffrant de schizophrénie : implication des systèmes de soin et conséquences médicoéconomiques. L'Encéphale, vol.35, pp.394-403, 2009. ,
Durées d'hospitalisation des patients souffrant de schizophrénie : facteurs cliniques de variations et leurs conséquences. L'Encéphale, vol.35, pp.90-96, 2009. ,